The non-cystic fibrosis bronchiectasis (NCFB) market is experiencing growth due to rising prevalence and increased awareness, leading to early diagnosis and treatment.
Phase 2 AIRLEAF trial results indicate that BI 1291583, a cathepsin C inhibitor, reduces the risk of pulmonary exacerbations in adults with bronchiectasis.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.